IGF-1 LR3, a laboratory-made version of a natural growth signal sold as a research chemical for bodybuilding and longevity, is untested in people. Evidence comes from animals and the natural hormone, where swelling, low blood sugar and eye changes were documented. Low and high natural levels track higher death rates, high levels more of several common cancers; for mid-range adults, evidence describes an unmeasured push away from the lowest-risk middle. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum IGF-1 | 120–160 ng/mL | Tracks own IGF-1 suppression and mortality-curve position |
| Fasting plasma glucose | 70–99 mg/dL | Detects hypoglycaemia, the acute dose-limiting event |
| Glycated haemoglobin (HbA1c) | 4.0–5.6% | Integrated glucose control over about three months |
Cadence: Baseline before any exposure (IGF-1, fasting glucose, glycated haemoglobin, dilated back-of-the-eye examination, age- and sex-appropriate cancer screening); pre-meal glucose checks from initiation until a dose is tolerated, then whenever symptoms recur; periodic back-of-the-eye examination; by common practice, IGF-1 and glycated haemoglobin at roughly 4–6 weeks, then every 3–6 months.